miONCO
Multi-Cancer Early Detection (MCED)
Pre-clinicalActive
Key Facts
About Xgenera
Xgenera is an Oxford-based private biotech founded in 2019, pivoting from its initial gene therapy focus to become a diagnostics company specializing in early cancer detection. Its core asset is the miONCO test, a multi-cancer early detection platform currently in a large-scale retrospective clinical trial. The company has secured non-dilutive grant funding and venture capital, positioning it to advance its technology through clinical validation and towards commercialization.
View full company profileTherapeutic Areas
Other Multi-Cancer Early Detection (MCED) Drugs
| Drug | Company | Phase |
|---|---|---|
| OneTest for Cancer | 20/20 BioLabs | Commercial |
| Early Cancer Detection | Burning Rock Biotech | R&D/Clinical Studies |